Central Nervous System Cancers

• DOI: 10.6004/jnccn.2013.0132
• Publication Date: 2017-04-14T12:03:46Z
• Authors: Louis Burt Nabors; Mario Ammirati; Philip J. Bierman; Henry Brem; Nicholas Butowski; Marc C. Chamberlain; Lisa M. DeAngelis; Robert A. Fenster...; Allan Friedman; Mark R. Gilbert; Deneen Hesser; Matthias Holdhoff; Larry Junck; Ronald Lawson; Jay S. Loeffler; Moshe H. Maor; Paul L. Moots; Tara Morrison; Maciej M. Mrugala; Herbert B. Newton; Jana Portnow; Jeffrey J. Raizer; Lawrence Recht; Dennis C. Shrieve; Allen K. Sills; David Tran; Nam Tran; Frank D. Vrionis; Patrick Y. Wen; Nicole McMillian; Maria Ho
• Keywords: Anaplastic astrocytoma

Primary and metastatic tumors of the central nervous system are a heterogeneous group neoplasms with varied outcomes management strategies. Recently, improved survival observed in 2 randomized clinical trials established combined chemotherapy radiation as new standard for treating patients pure or mixed anaplastic oligodendroglioma harboring 1p/19q codeletion. For disease, increasing evidence supports efficacy stereotactic radiosurgery multiple lesions but low overall tumor volume. These guidelines provide recommendations on diagnosis this diseases based panel consensus. This version includes expert advice low-grade infiltrative astrocytomas, oligodendrogliomas, gliomas, glioblastomas, medulloblastomas, supratentorial primitive neuroectodermal tumors, brain metastases. The full online version, available at NCCN. org, contains additional subtypes.